Myeloperoxidase Deficiency Inhibits Cognitive Decline in the 5XFAD Mouse Model of Alzheimer's Disease

Rotem Volkman1, Tali Ben-Zur1, Anat Kahana2

  • 1Department of Human Genetics and Biochemistry, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Frontiers in Neuroscience
|October 16, 2019
PubMed

Insights

Neutrophil myeloperoxidase (MPO) significantly contributes to Alzheimer's disease (AD) pathology in mice. Reducing MPO improved cognitive function and reduced inflammation, suggesting MPO as a therapeutic target for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Myeloperoxidase (MPO) is a neutrophil enzyme central to oxidative stress.
  • Evidence links MPO to Alzheimer's disease (AD) pathogenesis, but in vivo models are lacking.

Purpose of the Study:

  • To investigate the role of neutrophil-derived MPO in AD using the 5XFAD mouse model.
  • To assess the therapeutic potential of targeting MPO in AD.

Main Methods:

  • Created 5XFAD mice with hematologic MPO deficiency (5XFAD-MPO KO) via bone marrow transplantation.
  • Conducted behavioral tests (spatial learning, memory, anxiety).
  • Analyzed hippocampal inflammation, amyloid-β plaques, and APOE levels via immunohistochemistry, mRNA, and immunoblotting.

Main Results:

  • 5XFAD-MPO KO mice showed superior performance in learning, memory, and anxiety behaviors compared to controls.
  • Reduced inflammatory mediators were observed in the hippocampus of 5XFAD-MPO KO mice.
  • Amyloid-β plaque load remained unchanged, but APOE levels were reduced.

Conclusions:

  • Neutrophil-derived MPO plays a substantial role in the pathology of the 5XFAD AD mouse model.
  • Targeting MPO may offer a novel therapeutic strategy for Alzheimer's disease.